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Conclusions: EPID-based in vivo dosimetry was successfully 
implemented across 4 cancer centres. Results were comparable with 
those of alternative approaches but without increasing the time 
required for the treatment appointment. Detailed understanding of 
the equipment involved is important when relying on EPIDs for 
dosimetry. A dedicated team of champions is essential for driving 
forward changes to existing workflows. EPIDs can successfully be 
utilised for photon output checks. 
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Purpose/Objective: The main objective of this work was to model an 
electronic portal imaging devices (EPID) in a commercial Treatment 
Planning System (TPS). An EPID based transmitted dose verification 
model was developed to predict transmitted doses. This model 
enables the verification of two dimensional dose distribution in EPID 
level for a step and shoot intensity modulated radiation therapy 
(IMRT) technique using a SIEMENS Optivue 1000ST amorphous silicon 
portal imaging device. The model is user-friendly and does not involve 
complicating and time consuming analytical methods. 
Materials and Methods: A homogeneous PMMA phantom was scanned 
using a CT scanner. The CT scan of this phantom was transferred via 
DICOM files to the planning system. The central pixel response and 
profile characteristics were investigated to find the best EPID model 
in the TPS. To remove the effect of different sensitivity of EPID pixels, 
the flood field images have been obtained and used for correcting 
images. Portal images for several rectangular fields at different 
phantom thicknesses obtained to correct the field size dependency of 
the EPID detector. A two dimensional array of ionization chambers 
were used as reference for dose calibration of EPID portalimages at a 
specific depth; dref which the EPID dose profiles were best matched 
with the corresponding dose profiles measured in water in the TPS. 
Results: Predicted transmitted dose maps of 7 IMRT pelvic cases in a 
Phantom in EPID model were generated in the treatment planning 
system using collapsed cone algorithm. Predicted transmitted dose 
maps were compared with the corresponding two dimensional 
measured calibrated dose map using a calibrated EPID. Gamma 
analysis was used for comparison of predicted and measured dose 
maps. Results showed that approximately more than 95% of points in 
the dose maps of IMRT fields were in agreement with a 4% dose and 4 
mm distance criteria. 
Conclusions: The current technique can be applied for clinical dose 
verification as a simple and fast assessment method to verify IMRT 
treatments.  
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Purpose/Objective: The purpose of this research is to develop and 
verify an in-house program to calculate the monitor unit (MU) for 
proton therapy system equipped with the range modulation wheel 
(RMW). 
Materials and Methods: The MU calculation for the proton beam was 
suggested by Sahoo et al. in 2008 and given by the formalism using the 
multiplication of several factors with regard to the structure of the 
proton beam system. We adopted their theory and used eight factors 
in the equation for creating the program as follows: Relative output 
factor (ROF), Spread-out Braggpeak factor (SOBPF), Range shifter 
factor (RSF), SOBP off-center factor(SOBPOCF), Off-center ratio 
(OCR), Field size factor (FSF), Inverse square factor (ISF), and 
Compensator and patient scatter factor (CPSF). The program was built 
by Microsoft Visual Basic on Windows personal computer. After 
building the program, the calculated doses were compared with the 
measured dose. The referential dose was calibrated with an ionization 
chamber placed at the isocenter with a fixed source-to-detector 
distance (SDD) of 270 cm. 
Results: The program was created by Visual Basic ver.6.0 and verified 
under the environment of Windows 7 OS, 4 GB memory, 2.5GHz CPU. 
It was simply and satisfactory fast for the user to complete calculating 
(dose/MU). The graphical user interface (GUI) of our program is shown 
in Figure.1. The dose/MU was calculated by the equation with the 
multiplication using eight factors. The equation was given by: 
(dose/MU)=ROF*SOBPF*RSF*SOBPF*OCR*FSF*ISF*CPSF. Once the energy 
and the radiation field settings were input to the program, these 
factors were estimated from the referential measured data. Then MU 
calculation was done immediately. As the results of the comparison 
between the measured and calculated doses, the errors between the 
calculated and measured doses in all referential settings were within 
2%. Our program was able to calculate MU accurately in simple field 
settings. However, the errors in complicated radiation fields were 
larger than those of simple fields. In particular, ROF and SOBPF were 
commonly factors leading to large changes in d/MU. 
 
 
Figure 1. The main menu in our in-house program. 
 
Conclusions: The in-house program provides the fast MU calculation 
for proton beams as an independent check. The accuracy of the dose 
calculation is good in the referential settings at SDD of 270 cm. 
However, further improvement is required for the complicated 
settings.  
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Purpose/Objective: At the present, IMRT is a standard treatment 
modality and VMAT is becoming an increasingly common delivery 
technique; the complexity of these techniques makes patient-specific 
verification to be considered a prerequisite to patient treatment. 
Characteristics of modern EPIDs along with specific developed 
algorithms to process EPID response make these devices promising 
candidates for such dosimetry. The purpose of this work is to describe 
our initial experience using Varian® Portal Dosimetry in patient-
specific pretreatment verifications of RapiArc (RA) treatments. 
Materials and Methods: Our department has recently (February 2012) 
been equipped with 3 Varian linac’s (2 Clinac’s, 1 TrueBeam), in 
which a large part of the treatments are delivered with IMRT, mostly 
RA; dose distribution calculations are performed with Eclipse™ 
treatment planning system (10.0). The three linacs come with EPID 
sytems and Portal Dosimetry software (10.0) that allows for 
comparison between predicted images and acquired ones. The 
software is based on the EPID response calibration and a pencil beam-
based algorithm (PDIP) that predicts the system response. Our IMRT 
verification protocol includes Portal Dosimetry as one of the patient-
specific verification tools; one predicted image is generated for each 
of the arcs used; a calibration 10x10 static field is acquired prior to 
the verification in order to account for eventual minor changes in the 
detector response or linac output; for comparison,local gamma index 
(3%/3mm) is used discarding doses below a 10% threshold. The points 
passing rate is evaluated to assess the acceptability of the plan. 
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Results: A total of 325 IMRT treatment verifications have been 
performed (315 RA), with more than 700 portal images analyzed. 
Although we use a quite restrictive protocol (local gamma index) the 
average number of points that passed the mentioned criterion has 
been 95.1% (range: 83.5 – 99.9,std dev: 4%). The worse cases results 
have been found in IMRT static fields (like mantle type fields), in 
complex cases (non-coplanar 6 arcs treatment, very large fields even 
exceeding the detector size) and in RA plans with a large number of 
arcs in which the acquired images show a pattern of regions with large 
portions shielded.  We use Portal Dosimetry in each IMRT plan prior to 
treatment due mainly to the characteristics of the detector, but it has 
to be used in conjunction with other dosimetric systems. On one side 
are the limitations of the prediction algorithm, and on the other it is 
difficult to establish the acceptance levels for gamma analysis results 
especially for RA where the whole arc is acquired in one image. 
Conclusions: Portal Dosimetry is being used in routine in IMRTpre-
treatment patient-specific verifications. For most of the cases pass 
rates are quite high, but another two systems are used in conjunction 
in order to decide the acceptability of the plan. Specific acceptance 
levels guidances provided by vendor would be very helpful to users. 
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Purpose/Objective: Total body irradiation treatments are usually 
checked with in-vivo dosimetry measurements. In our institution we 
use a diodes-based in-vivo dosimetry system, composed of diodes, 
electrometer and software. A single failure in one of the components 
may make the system unusable. We aimed to evaluate Gafchromic 
EBT2 radiochromic film (International Specialty Products) as a backup 
system for diodes to perform in-vivo dosimetry for total body 
irradiation treatments. 
Materials and Methods: EBT2 films readings were compared to a 
Farmer 30013 chamber (PTW) and EDP-15 diodes (IBA) in a solid water 
phantom, in TBI conditions: 6 MV photon beam (Varian 2100 linac), 
40x40 cm2 field, SSD=315 cm, 1 cm PMMA beam spoiler. Films were 
located at the phantom surface, under a 1 cm bolus slab. Diodes were 
also at surface and ionization chamber was situated at phantom mid-
plane (9 cm depth). Two films were irradiated each time. EBT2 films 
were tested for post-irradiation time influence, linearity, accuracy 
and reproducibility. We also measured attenuation of bolus+film and 
assessed the influence of interruptions during irradiation. A film inside 
the phantom measured a PDD curve. Red channel calibration was used 
to read the films. The method was clinically tested in three patients: 
a 2x2 cm2 piece of film was affixed to patient's skin (at abdomen) 
below a 1 cm bolus slab. Film reading was converted to mid-plane 
dose and compared with diode readings. 
Results: We found that films response remains stable after around 24 
h. Dose linearity was excellent in the range 10-200 cGy. PDD 
measurement showed a dose value at mid-plane of 79.3% of maximum 
dose, while PDD measured with ionization chamber showed a value of 
80.4%. Film dose readings were within 3% respect to chamber dose 
values (mean -1.6%), except for one film (6%). Difference between 
film and diodes were within 4.6% (mean -3.2%), except for one film 
(7.5%). Film reproducibility was within 2% (10 films). Since one of the 
films showed a very different dose from the mean value (6%), 
reproducibility would drop to 1.4% if this film was not considered. No 
significant influence of interruption time was detected for an 
interruption time up to 6 min. Bolus slab and EBT2 film produced an 
attenuation of 2.5% at phantom mid-plane. Results from the three 
patients studied showed a deviation of 2.5%, 3.1% and 2.0% between 
EBT2 films and diodes. 
Conclusions: We developed a practical method to use EBT2 film as a 
backup system for diodes in TBI in-vivo dosimetry. Mean film dose 
readings differed from diodes less than 3.5%, in phantom and clinical 
conditions. EBT2 films are an adequate in-vivo dosimeter provided 
some precautions are taken: films should be read 24 h after 
irradiation and we recommend using at least 2 pieces of film for each 
location, and set up the bolus slab with film at a different position 
each session to diminish the attenuation effect. 
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Purpose/Objective: TomoDirectTM (TD) is a non-rotational treatment 
option implemented on the TomoTherapy Hi-Art system (Accuray, 
Inc., Sunnyvale, CA). It stands as an alternative to conventional linac 
system, allowing to deliver IMRT treatments with a static gantry 
position. With the introduction of TD new potentialities for the 
treatment of the whole breast are now available. Since some 
protocols recommended to systematically check the absorbed dose 
delivered in new treatment techniques to a patients’ sample 
implementing in-vivo dosimetry protocol, we decided to study the 
effectiveness of MOSFET (TN-502 RDM-H standard microMOSFET 
Thomson & Nielsen, Ottawa, ON Canada) as in-vivo dosimeters during 
TD treatment of breast cancer. 
Materials and Methods: The MOSFETs were calibrated against an 
ionization chamber type Exradin A1SL (Standard Imaging, Middleton, 
WI) using a modulated TD beam calculated on PMMA phantom. The 
entrance and exit dose calibration factors were determined in a solid 
water phantom positioning the MOSFET with the required 
hemispherical brass build-up cup. To verify the MOSFET effectiveness 
during in vivo dosimetry, dose measurements were performed on 
whole breast treatment plans created using TD two opposed 
tangential beams technique on an anthropomorphic Rando female 
thorax phantom (Phantom Laboratory, Salem, New York). 
Measurements were performed positioning MOSFET at the medial side 
on a point coincident with the red laser at 5 cm from radiopaque 
alignment marker and at the lateral side on the same defined 
reference point. This process was repeated several times to evaluate 
the reproducibility and accuracy of MOSFET measurements during 
treatment on a Tomotherapy Hi-Art unit. In vivo dosimetry was then 
performed on a total of 15 whole breast patients using the same 
procedure. Discrepancies between measured and calculated values for 
TD treatments have been evaluated. 
Results: The reproducibility of the MOSFET response is found to be 
better than 2.5% for the doses normally delivered to the patients. The 
difference between the MOSFET measured dose on Rando phantom 
and the planned dose at each point was less than 4%, with an average 
of -0.8 %± 1.7%. In vivo dose measurements show that the dose 
difference between MOSFET results and the TPS calculations was on 
average -0.7%, ranging from -4.7% to 4.8% with a standard deviation of 
the measurements of each patient less than 3%. 
Conclusions: In conclusion, MOSFET detectors are suitable for routine 
TD dose verification. 
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Purpose/Objective: The aim of this study is to develop a novel dose-
verification method for intensity-modulated radiotherapy (IMRT) that 
expands upon the traditional DTA (extended DTA) by adding 
displacement directions to the distance difference. 
Materials and Methods: The extended DTA was acquired by measuring 
the distance between the isodose lines obtained from theTreatment 
Planning System (reference isodose line) and the film dosimetry 
(evaluation isodose line) (EDR2 Films: EastmanKodak Company;) of the 
prostate IMRT case. The extended DTA is the difference between the 
points at which the reference and evaluation isodose line intersect 
with a straight line after every 10° with respect to the origin. 
Furthermore, the distance of the difference was determined as both 
'negative' and 'positive' if the evaluation isodose lines were both inside 
and outside the reference isodose lines, respectively. This latter 
assessment is useful because some reference isodose lines show low 
and high doses. The extended DTA was represented by 2D difference 
maps that use cylindrical projection. These maps show the angle in 
the horizontal axis, the dose in the vertical axis and the distance of 
difference (in millimeters) with the color scale. The extended DTA 
was performed by an in-house program and compared with the gamma 
analysis and the DTA using an OmniPro ImRT (IBA Dosimetry). The 
criterion value used for the gamma analysis and the DTA was 2mm3%, 
2mm. DTA was 2mm3%, 2mm. The extended DTA was calculated using 
max dose and 100%, 97%, 95%, 93%, 90% and 80% of the isodose lines. 
Results: The extended DTA in the 2D difference map showed a value 
